<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389413</url>
  </required_header>
  <id_info>
    <org_study_id>PBD01071</org_study_id>
    <secondary_id>2014-001967-11</secondary_id>
    <nct_id>NCT02389413</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease</brief_title>
  <acronym>SAPHIR</acronym>
  <official_title>A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probiodrug AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Julius Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Probiodrug AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of
      PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild
      dementia due to AD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory clinical measures (measured by a questionnaire)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mini-Mental State Examination (MMSE) Letter Fluency Test (LFT) Category Fluency Test (CFT) Geriatric Depression Scale (GDS) Cogstate Neuropsychological Test Battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of a panel of concept and AD-related biomarkers in Cerebrospinal fluid (CSF) (measured by Analysis of several biochemical assays)</measure>
    <time_frame>12 weeks</time_frame>
    <description>QC activity, total-tau, phospho-tau, Abeta pattern, pro-inflammatory panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in brain functional connectivity (measured by Magnetic Resonance Imaging (MRI) analysis)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional connectivity and network Analysis in electroencephalography (EEG)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>PQ912 oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PQ912 will be administered orally twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQ912 oral</intervention_name>
    <arm_group_label>PQ912 oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Signed and dated written informed consent

          -  Male or surgically sterile or postmenopausal female aged ≥ 50 to ≤ 89 years. Male
             subjects with childbearing potential partners are willing to and should use condoms
             during treatment and until 28 days of the last dose of study medication.

          -  Diagnosis of MCI due to AD or mild dementia due to AD with amnestic presentation,
             according to AA-NIA (Alzheimer's Association (AA) and the National Institute on (Aging
             NIA) criteria [Albert et al 2011; McKhann et al 2011]

          -  Mini-Mental State Examination (MMSE) score of 21 to 30 inclusive at screening

          -  A positive AD signature showing one of the following (either a, b, c, OR d):

               1. Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND
                  total tau &gt;375 ng/L, as assessed by central laboratory.

               2. Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND
                  p-tau &gt; 52 ng/L, as assessed by central laboratory.

               3. Tau/A-beta ratio &gt; 0.52, as assessed by central laboratory.

               4. A positive amyloid PET if available prior to screening.

          -  Treatment naïve, this means not having received any prior established specific
             treatment for MCI due to AD or mild dementia due to AD including no (prior) use of an
             acetylcholinesterase inhibitor or memantine. A maximum of two months of prior
             cumulative treatment with an acetylcholinesterase inhibitor or memantine is allowed if
             the acetylcholinesterase inhibitor or memantine was discontinued due to intolerance,
             and if this was done at least two months prior to baseline. Use of Souvenaid will be
             allowed if Souvenaid was discontinued at least twomonths prior to baseline, or if the
             subject is on stable dose for at least six months prior to baseline and is willing to
             continue during the study on the same dose and frequency.

          -  Outpatient with study partner capable of accompanying the subject on all clinic
             visits. In accordance to Swedish regulations availability of study partner is not
             applicable for Sweden.

        Major Exclusion Criteria:

          -  Significant neurologic disease, other than AD, that may affect cognition.

          -  Atypical clinical presentations of MCI due to AD or mild dementia due to AD, such as
             the visual variant of AD (including posterior cortical atrophy) or the language
             variant (including logopenic aphasia).

          -  Concomitant disorders:

               -  Severe hepatic (Child-Pugh C) and/or kidney failure (creatinine clearance
                  (estimated Glomerular Filtration Rate - eGFR) ≤ 30 ml/min/1.73m2) and/or serum
                  creatinine above 1.5 fold of Upper Limit Normal (ULN) and/or Alanine-Amino
                  Transferase (AST) or Asparagine-Amino Transferase (ALT) above 3 fold ULN at
                  baseline.

               -  History of or screening visit brain MRI scan indicative of any other significant
                  abnormality.

               -  Current presence of a clinically important major psychiatric disorder (e.g. major
                  depressive disorder) as defined by DSM-5 criteria, or symptom(s) (e.g.
                  hallucinations) that could affect the subject's ability to complete the study.

               -  . Current clinically important systemic illness that is likely to result in
                  clinically relevant deterioration of the subject's condition or might affect the
                  subject's safety during the study.

               -  Other clinically important diseases or conditions or abnormalities of vital
                  signs, physical examination, neurologic examination, laboratory results, or
                  electrocardiogram (ECG) examination (e.g. atrial fibrillation) that could
                  compromise the study or the safety of the subject.

               -  Clinically important infection within 30 days prior to screening e.g. chronic
                  persistent or acute infection, such as bronchitis or urinary tract infection.

               -  Any known hypersensitivity to any of the excipients contained in the test article
                  formulation.

               -  Severe hepatic failure (Child-Pugh C) OR kidney failure (creatinine clearance
                  (eGFR) ≤ 30 ml/min/1.73m2) OR serum creatinine above 1.5 fold of ULN OR AST or
                  ALT above 3 fold of ULN at screening.´

          -  Concomitant Medication/Therapies:

        The following therapies are not permitted for the given intervals prior to baseline and
        until End-of-treatment (EOT):

          -  Use of experimental medications for AD or any other investigational medications or
             devices for treatment of indications other than AD within 60 days prior to baseline.

          -  Treatment with Souvenaid, except if the use of Souvenaid was discontinued at least two
             months prior to baseline, or if the subject is on stable dose for at least six months
             prior to baseline and is willing to continue the use of Souvenaid during the study on
             the same dose and frequency.

          -  Concomitant treatment with St. John's Wort (a wash out phase of at least two weeks
             prior to baseline is required).

          -  Any concomitant treatment which impairs cognitive function and cannot be washed out at
             least four weeks prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Weber, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Probiodrug AG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Scheltens, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>VUmc Alzheimer Centre (p: +31 20 4440816)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen / Geheugenkliniek</name>
      <address>
        <city>Hoboken</city>
        <zip>2660</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliininen tutkimuskeskus</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRST Oy</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Pellegrin (CMRR)</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU François Mitterand (Centre Mémoire Ressources Recherche (CMRR))</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille / Hôpital Roger Salengro</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Grave / Centre de Recherche Clinique</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen / Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzneimittelforschung Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster / Klinik für Allgemeine Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock / Zentrum für Nervenheilkunde/ Klinik für Psychosomatik und Psychotherapeutische Medizin</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer Research Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau, Neurology Department, Memory Unit</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació ACE. Institut Català de Neurociències Aplicades</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago (CHUS)</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verksamheten för neuropsykiatri Sahlgrenska universitetssjukhuset</name>
      <address>
        <city>Mölndal</city>
        <zip>43141</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PQ912</keyword>
  <keyword>Glutaminy Cyclase (QC)</keyword>
  <keyword>QC - Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

